BRIEF—Teva adds to generic women's health portfolio with US launch

Israeli drugmaker Teva (NYSE: TEVA) has announced the launch of an authorized generic of Estrace Cream (estradiol vaginal cream, USP, 0.01%) in the USA.

This cream, which is indicated in the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, had annual sales of approximately $426 million in the USA, according to IQVIA data from August 2017.